Microbial Products and Biotechnological Applications Thereof: Proteins, Enzymes, Secondary Metabolites, and Valuable Chemicals

Dabbagh, Fatemeh; Moradpour, Zahra; Ghasemian, Abdollah

doi:10.1007/978-981-32-9084-6_18

Cited by 5 publications

(2 citation statements)

References 282 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Micromonospora has grabbed attention due to the secondary metabolites production along with a group of welldocumented valuable antibiotics, especially aminoglycosides, enediynes, and oligosaccharides [11,29,30]. The current study has focused on revealing the antimicrobial activity of Micromonospora strains isolated from Egyptian habitats against antibiotic-resistant enteric pathogens.…”

Section: Discussionmentioning

confidence: 99%

“…According to records, over 88 Micromonospora species recovered from several environments produced various bioactive metabolites [9]. Micromonospora strains are also known for their potential to produce plant growth promoters [10] and various antibiotics including, aminoglycosides, enediynes, and oligosaccharides [11]. For such valuable strains, metagenomics-based approaches, and modern metabolomics-inspired methods greatly help improve access to novel natural product and comprehensively exploit its full potential [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unlocking the Potential of Micromonospora sp.: Metabolomics and Molecular Modeling to Combat Antibiotic Resistance in Enteric Pathogens via ATP Synthase Inhibitors

El-Shatoury,

Megawer,

Nafie

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The misuse of antibiotics in the last decade led to the quick emergence of antibiotic resistance among pathogenic microorganisms. It has become a serious health problem that motivates researchers to explore new antimicrobial compounds. Micromonospora is one of the most important producers of commercially successful secondary bioactive metabolites, especially antibiotics such as aminoglycosides, enediynes, and oligosaccharides. This study highlights the potential of Micromonospora spp. as a source of novel antibacterial agents against multidrug resistant human enteric pathogens. Results The metabolic extract from Micromonospora sp. 65SH showed the lowest MIC against Enterobacter sp. (25 µg/ml) and E. coli (12.5 µg/ml). We performed 16S rRNA gene sequencing to confirm the isolate’s identification at the genus level. Non-targeted metabolomics and molecular LC-QTOF-MS-MS modeling technique were used to identify potential compounds, mechanisms of action and target sites for new antibiotics derived from Micromonospora sp 65SH. The non-targeted metabolomics and molecular modeling of strain 65SH have shown six inhibitors to interfere with the E. coli ATP synthase and possible direct inhibitory effect on the ATP-dependent bacterial topoisomerases. These are: Melibiose, Oligomycin A, Queuine, Heptelidic acid, Diethyl phthalate, and 2'-Deoxyguanosine. Conclusion This research on Micromonospora metabolites holds promise for identifying unique compounds, understanding their mechanisms of action, and ultimately developing innovative strategies to target ATP synthase and address various diseases or conditions associated with aberrant energy metabolism. As scientists delve deeper into this relatively unexplored area, the future holds exciting prospects for the discovery and development of Micromonospora-derived ATP synthase inhibitors to combat antibiotic resistance.

show abstract

Section: Discussionmentioning

confidence: 99%